There are 483 papers on glycated hemoglobin in aging research: 95 trials and 273 observational studies in people, 15 in animals, 85 reviews.
117 new papers in 30 daysSee all 1,299 papers on glycated hemoglobin
At a glance
Higher glycated hemoglobin is linked with mortality in older patients with femoral neck fractures and, in a preprint, with frailty in community-dwelling Chinese adults. Human studies also link it with cognition, handgrip strength and gait speed; human trials report lower levels with exercise and several diabetes drugs.
187 findings in 158 papers from 1984 to 2026, 30 of them since June 2026
“Baseline and average HbA1c levels over time of <7%, as compared with ≥8%, were associated with less increase in FI scores over 8 years (both P ≤ 0.002).”
- Human trial95
- Humans273
- Animals15
- In silico6
Interventions
64Tirzepatide
downin humans16upin humans1
17 studies
Tirzepatide
downin humans16upin humans1
Tirzepatide decreases glycated hemoglobin in humans (severe MASH and diabetes; switched from liraglutide).
“Over 6 months of administration of tirzepatide, the patient's glycated hemoglobin and elevated liver enzyme levels improved.”
Human trialsevere MASH and diabetes; switched from liraglutide6 monthsmalesn = 1
Frontiers in endocrinology
Tirzepatide decreases glycated hemoglobin in humans (vs dulaglutide; post hoc split by baseline C-peptide (cutoff 1.86 μg/l)) (C-peptide <1.86 μg/l: -2.31% to -2.75% vs -1.45%; ≥1.86 μg/l: -2.43% to -2.89% vs -1.12%).
“the tirzepatide groups showed significant improvement in glycated hemoglobin at week 52 compared with the dulaglutide group”
Human trialvs dulaglutide; post hoc split by baseline C-peptide (cutoff 1.86 μg/l)5, 10, 15 mg once weekly52 weeksn = 636
Diabetes therapy : research, treatment and education of diabetes and related disorders
Tirzepatide decreases glycated hemoglobin in humans (compared with placebo, in T2DM patients with overweight/obesity) (-1.64 (-1.94, -1.35) vs placebo).
“Tirzepatide showed superior effects in lowering blood glucose (Compared with placebo, increased glycated hemoglobin: -1.64 (-1.94, -1.35)”
Human trialcompared with placebo, in T2DM patients with overweight/obesity
Diabetes research and clinical practice
Tirzepatide decreases glycated hemoglobin in humans (adjusted indirect comparison versus semaglutide 0.5 mg).
“All tirzepatide doses showed statistically significantly greater reductions in glycated haemoglobin, body weight and body mass index from baseline to week 40”
Human trialadjusted indirect comparison versus semaglutide 0.5 mg5, 10 and 15 mgweek 40
Diabetes research and clinical practice
Tirzepatide decreases glycated hemoglobin in humans (ranked in the top three by network meta-analysis).
“Tirzepatide 15 mg ranked in the top three across weight-related parameters, glycemic profile (glycated hemoglobin)”
Human trialranked in the top three by network meta-analysis15 mg
Obesity (Silver Spring, Md.)
Tirzepatide decreases glycated hemoglobin in humans (compared with basal insulin and selective GLP1-RA in network meta-analysis) (SCURA probability 93.5%).
“15 mg of tirzepatide was dominant on reducing glycated hemoglobin (SCURA probability: 93.5%)”
Human trialcompared with basal insulin and selective GLP1-RA in network meta-analysis15 mg
Frontiers in pharmacology
Tirzepatide decreases glycated hemoglobin in humans (compared with semaglutide 1 mg; largest difference at 15 mg) (-0.45 percentage points for 15 mg versus semaglutide (95% CI -0.57 to -0.32); -0.15 and -0.39 for 5 and 10 mg).
“Tirzepatide at all doses was noninferior and superior to semaglutide.”
Human trialcompared with semaglutide 1 mg; largest difference at 15 mg15 mg40 weeksn = 1,879
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
The New England journal of medicine
Tirzepatide is linked with lower glycated hemoglobin in humans (compared with matched controls) (-0.50 ± 0.07% vs -0.24 ± 0.09% in controls; P = 0.017).
“The HbA1c decreased more in patients using tirzepatide than controls (-0.50 ± 0.07% and -0.24 ± 0.09%, respectively, P = 0.017).”
Humanscompared with matched controls21 monthsn = 84
Diabetes technology & therapeutics
Tirzepatide is linked with lower glycated hemoglobin in humans (compared with GLP-1 RA in adults with type 2 diabetes) (treatment difference -0.34 percentage points (95% CI -0.44 to -0.24)).
“Treatment with tirzepatide was associated with greater decreases in glycated hemoglobin (treatment difference, -0.34 percentage points; 95% CI, -0.44 to -0.24 percentage points)”
Humanscompared with GLP-1 RA in adults with type 2 diabetes
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
JAMA network open
Tirzepatide improves glycated hemoglobin in humans (compared with semaglutide).
“Tirzepatide was also associated with greater improvements in blood pressure and glycated haemoglobin”
Reviewcompared with semaglutide
Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review
Cureus
All 17Fewer
Acarbose
downin humans6no changein humans1downin rats1
8 studies
Acarbose
downin humans6no changein humans1downin rats1
Acarbose decreases glycated hemoglobin in humans (-0.79% to -1.32% across baseline glucagon tertiles).
“Significant reductions in HbA1c were observed in both acarbose and metformin groups at 24 and 48 weeks”
Human trial300 mg/day24 and 48 weeks
Diabetes research and clinical practice
Acarbose decreases glycated hemoglobin in humans (compared with metformin; similar reduction in all beta-cell function groups) (similar to metformin; no values given).
“both acarbose and metformin could decrease glycated hemoglobin to similar levels after 48 weeks treatment in all groups”
Human trialcompared with metformin; similar reduction in all beta-cell function groups300 mg/d48 weeks
Endocrine journal
Acarbose decreases glycated hemoglobin in humans (-1.8% points (HbA1c); -2.4% points (HbA1)).
“Over the 5 years, HbA(1) and glycated haemoglobin (HbA(1c)) decreased by 2.4 and 1.8% points, respectively”
Human trial5 years
Diabetes research and clinical practice
Acarbose decreases glycated hemoglobin in patients with inadequate control on diet and sulphonylureas (from 8.36 to 7.71%).
“glycosilated hemoglobin decreased from 8.36 +/- 1.33 to 7.71+ 1.7% (p < 0.001)”
Human trialin patients with inadequate control on diet and sulphonylureas150 mg/day for 4 weeks, then 300 mg/day for 3 monthsn = 64
Revista medica de Chile
Acarbose showed no clear effect on glycated hemoglobin in humans (versus placebo).
“fasting glucose and % HbAl concentrations were not different from those observed during placebo therapy”
Human trialversus placebo300 mg/dayone monthn = 18
Treatment of poorly controlled non-insulin-dependent diabetic patients with Acarbose
Australian and New Zealand journal of medicine
Acarbose decreases glycated hemoglobin in humans (mainly via its effects on postprandial hyperglycemia).
“Agents such as acarbose, which has been shown to reduce 24-h glycemia and glycated hemoglobin”
Reviewmainly via its effects on postprandial hyperglycemia
Expert review of endocrinology & metabolism
Acarbose decreases glycated hemoglobin in humans (as monotherapy and as add-on to other antidiabetic drug treatment).
“Treatment with acarbose significantly reduced glycated hemoglobin levels when given as monotherapy and as an add-on to other antidiabetic drug treatment (P < 0.0001).”
Reviewas monotherapy and as add-on to other antidiabetic drug treatment
Clinical therapeutics
Acarbose decreases glycated hemoglobin in rats (non-diabetic rats compared with untreated controls).
“acarbose-treated non-diabetic control rats who demonstrated decreased glycated hemoglobin levels compared to non-treated control rats.”
Animalsnon-diabetic rats compared with untreated controls
Diabetes research and clinical practice
SGLT2 inhibitors
downin humans4
4 studies
SGLT2 inhibitors
downin humans4
SGLT2 inhibitors are linked with lower glycated hemoglobin in humans (patients with type 2 diabetes starting SGLT2i after age 70) (7.8 ± 1.1 to 7.1 ± 0.8%, p < 0.001).
“A statistically significant reduction of glycated hemoglobin (baseline vs 12 months: 7.8 ± 1.1 vs 7.1 ± 0.8%, p < 0.001)”
Humanspatients with type 2 diabetes starting SGLT2i after age 7012 months
SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
Pharmacological research
SGLT2 inhibitors decrease glycated hemoglobin in patients with diabetic CKD (MD = -0.40%, 95% CI: -0.44 to -0.36).
“SGLT2 inhibitors significantly reduced glycated hemoglobin levels (MD = -0.40%, 95% CI: -0.44 to -0.36)”
Reviewin patients with diabetic CKD
Medicine
SGLT2 inhibitors decrease glycated hemoglobin in humans (type 1 diabetes; add-on to insulin pump therapy) (MD -0.30%, 95% CI -0.41 to -0.20).
“Glycated hemoglobin decreased significantly (MD -0.30%, [-0.41 to -0.20]);”
Reviewtype 1 diabetes; add-on to insulin pump therapy
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
SGLT2 inhibitors decrease glycated hemoglobin in humans.
“Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors are newer antihyperglycemic agents that effectively lower glycated hemoglobin levels”
Review
The Journal of family practice
GLP-1 receptor agonists
downin humans2downin reviews1
3 studies
GLP-1 receptor agonists
downin humans2downin reviews1
GLP-1 receptor agonists are linked with lower glycated hemoglobin in humans (−1.6 percentage points (SD 1.3), from baseline 8.3%).
“By the end of the study, patients reduced their glycated hemoglobin by 1.6% (SD = 1.3) from a baseline of 8.3%”
HumansType 2 diabetes; exit-interview sample from ACHIEVE-3, without a between-treatment comparisonOralBoth; 28 femalesn = 60
The patient
GLP-1 receptor agonists decrease glycated hemoglobin.
“Large clinical trials have supported GLP-1 RAs as an excellent option for reducing glycated hemoglobin and body weight, as well as for reducing major renal and cardiovascular adverse effects”
Review
Advances in therapy
GLP-1 receptor agonists decrease glycated hemoglobin in humans.
“Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors are newer antihyperglycemic agents that effectively lower glycated hemoglobin levels”
Review
The Journal of family practice
Semaglutide
downin humans3
3 studies
Semaglutide
downin humans3
Semaglutide is linked with lower glycated hemoglobin in humans (caution in interpreting magnitude and speed).
“Following the high dose of semaglutide, glycated hemoglobin decreased”
Humanscaution in interpreting magnitude and speed0.5mg/weekmalesn = 1
Simultaneous bilateral NAION following initiation of high-dose semaglutide: a case report
Archivos de la Sociedad Espanola de Oftalmologia
Semaglutide is linked with lower glycated hemoglobin in humans (as an add-on therapy to insulin in LADA patients).
“semaglutide users showed statistically significant reduction in glycated hemoglobin, body mass index, and insulin total daily dose.”
Humansas an add-on therapy to insulin in LADA patients6 monthsn = 68
The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults
The Journal of clinical endocrinology and metabolism
Semaglutide decreases glycated hemoglobin in humans (versus placebo in PIONEER 5) (ETD -0.8%; 95% CI -1.0, -0.6).
“oral semaglutide was superior to placebo in decreasing glycated hemoglobin over 26 weeks (estimated treatment difference [ETD]: -0.8%; 95% CI: -1.0, -0.6; p < 0.0001)”
Reviewversus placebo in PIONEER 5oral tablet formulation26 weeks
Postgraduate medicine
Resistance training
downin humans2no changein humans1
3 studies
Resistance training
downin humans2no changein humans1
Resistance training decreases glycated hemoglobin in humans (CKD undergoing maintenance hemodialysis).
“Glycated hemoglobin, inflammatory cytokines, and triglycerides decreased in RT and RT-CS groups as compared with pre-intervention and CG”
Human trialCKD undergoing maintenance hemodialysis24 weeksn = 78
Experimental gerontology
Resistance training showed no clear effect on glycated hemoglobin in humans (between-group comparison with active control).
“No significant differences were found for blood lipid profile and glycated hemoglobin for both groups after the intervention period.”
Human trialbetween-group comparison with active control12 weeks
Experimental gerontology
Resistance training decreases glycated hemoglobin in humans (mean difference -0.66 %, 95 % CI -1.01 to -0.33, p = 0.0002).
“glycated hemoglobin (mean difference -0.66 %, 95 % CI -1.01 to -0.33, p = 0.0002)”
Reviewin women with overweight or obesity who are middle-aged or older and have type 2 diabetes mellitusfemalesn = 315
Maturitas
Exercise
downin humans2
2 studies
Exercise
downin humans2
Exercise decreases glycated hemoglobin in humans (post-bariatric surgery, at 4 months) (-0.3%; 95% CI, -0.5 to -0.1).
“and glycated hemoglobin (- 0.3%; 95% CI, - 0.5 to - 0.1; p = 0.018) at 4 months.”
Human trialpost-bariatric surgery, at 4 monthsindividually supervised concurrent exercise trainingthree 60-min sessions/week16 weeksn = 80
Obesity surgery
Exercise decreases glycated hemoglobin in humans (Hedges’ g = −0.52).
“improved glucose metabolism, reducing FPG (Hedges’ g = −0.42, p < 0.001), HbA1c (Hedges’ g = −0.52, p < 0.001), and HOMA-IR (Hedges’ g = −0.48, p < 0.001”
Human trial6 to 52 weeksn = 2,578
Frontiers in nutrition
Exercise decreases glycated hemoglobin in patients with type 2 diabetes mellitus complicated by non-alcoholic fatty liver disease (Hedges' g = -0.52, p < 0.001).
“exercise reduced BMI (Hedges' g = -0.36, p < 0.001), FPG (Hedges' g = -0.42, p < 0.001), HbA1c (Hedges' g = -0.52, p < 0.001)”
Human trialin patients with type 2 diabetes mellitus complicated by non-alcoholic fatty liver disease
Frontiers in nutrition
Spermidine
downin humans1downin rats1
2 studies
Spermidine
downin humans1downin rats1
Spermidine decreases glycated hemoglobin in humans (cluster 3, highest baseline and increased 1-year spermidine intake) (-0.14 [-0.18 to -0.10]%).
“glycated hemoglobin levels (- 0.14 [- 0.18 to - 0.10]%, p-int < 0.01)”
Human trialcluster 3, highest baseline and increased 1-year spermidine intake1 year
Rising spermidine intake linked to better liver scores
European journal of nutrition
Spermidine decreases glycated hemoglobin in alloxan-induced diabetic rats.
“The L-arginine and spermidine injection tended to normalize the glycemia from 24 hours, similarly, hyperlipidemia, TBARS, and HbA(1C).”
Animalsin alloxan-induced diabetic rats10 microM
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Yoga
no changein humans1downin humans1
2 studies
Yoga
no changein humans1downin humans1
Yoga showed no clear effect on glycated hemoglobin in humans (type 2 diabetes mellitus) (from 6.74% to 6.47%, p=0.10).
“HbA1c levels decreased from 6.74% to 6.47%, however, this change did not reach statistical significance (p=0.10).”
Human trialtype 2 diabetes mellitus12-weekn = 12
ADA Scientific Sessions 2026 abstract
Yoga decreases glycated hemoglobin in humans (type 2 diabetes and non-alcoholic fatty liver disease).
“The cyclic yoga group showed significant reductions in fasting blood glucose, glycated hemoglobin, insulin resistance, triglycerides, low-density lipoprotein cholesterol”
Human trialtype 2 diabetes and non-alcoholic fatty liver diseaseeight-weekfemalesn = 40
Journal of clinical & translational endocrinology
Retatrutide
downin humans2−2.2%
2 studies
Retatrutide
downin humans2−2.2%
Retatrutide decreases glycated hemoglobin in subjects with type 2 diabetes mellitus (up to 2.16%).
“In subjects with type 2 diabetes mellitus (T2DM), decreased glycated hemoglobin (HbA1c) by up to 2.16%”
Reviewin subjects with type 2 diabetes mellitus
Retatrutide in type 2 diabetes mellitus and obesity: an overview
Expert review of clinical pharmacology
Retatrutide decreases glycated hemoglobin in individuals with type 2 diabetes, phase-2 trials.
“Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM).”
Reviewin individuals with type 2 diabetes, phase-2 trials
Retatrutide: a triple incretin receptor agonist for obesity management
Expert opinion on investigational drugs
Liraglutide
downin humans2
2 studies
Liraglutide
downin humans2
Liraglutide decreases glycated hemoglobin in humans (MD -0.19%; 95% CI -0.25 to -0.13).
“and HbA1c (MD -0.19%; 95% CI -0.25 to -0.13)”
Human trial
Diabetes, obesity & metabolism
Liraglutide decreases glycated hemoglobin in humans (−1.1% (95% CI −1.3 to −0.9)).
“The estimated treatment differences of all three liraglutide groups compared with the placebo group and the resulting 95% CIs demonstrated that liraglutide-treated subjects had superior glycemic control compared with those in the placebo group”
Human trial26 weeksn = 1,091
Diabetes care
High-fiber diet
downin humans1
1 study
High-fiber diet
downin humans1
High-fiber diet decreases glycated hemoglobin (6.32, 95% CI 6.11–6.53, vs. 6.74, 95% CI 6.39–7.09).
“At Day 84, the baseline-adjusted means were significantly lower in the W group than in the U group for both HbA1c (6.32, 95% CI 6.11–6.53, vs. 6.74, 95% CI 6.39–7.09; p = 0.042) and BMI (28.42 kg/m, 95% CI 28.07–28.78, vs. 30.22 kg/m, 95% CI 29.61–30.83; p < 0.001) ( Figures 1A, F; Supplementary Table S4”
Human trial84-day interventionn = 48
Frontiers in microbiology
High-fiber diet decreases glycated hemoglobin in humans.
“At Day 84, the high-fiber group had greater reductions in glycated hemoglobin and body mass index and lower glycemic variability than the metformin group.”
Human trialNewly diagnosed type 2 diabetes and overweight or obesity; compared with metformin monotherapy84 daysn = 48
Frontiers in microbiology
Health promotion model-based intervention
downin humans1
1 study
Health promotion model-based intervention
downin humans1
Health promotion model-based intervention decreases glycated hemoglobin in humans.
“Post-intervention assessments revealed declines in FPG and HbA1c levels in both groups, with the HPM group achieving significantly lower values than the conventional group (P<0.001).”
Human trialone monthn = 142
Journal of medical biochemistry
Health promotion model-based intervention decreases glycated hemoglobin in patients with hyperthyroidism complicated by diabetes mellitus (P< 0.001).
“significantly larger decreases in FPG, HbA1c, TC, and TG were identified in the HPM group (P< 0.001).”
Human trialin patients with hyperthyroidism complicated by diabetes mellitusn = 142
Journal of medical biochemistry
Multidisciplinary residential program
downin humans1
1 study
Multidisciplinary residential program
downin humans1
Multidisciplinary residential program decreases glycated hemoglobin in humans.
“In, regarding blood parameters, as there was a significant improvement in the overall values between pre and post recovery, it is noteworthy to mention how such intervention enhanced glycaemia (p < 0.05), glycosylated hemoglobin (p < 0.01), insulinemia (p < 0.05), total cholesterol (p < 0.001), LDL (p < 0.001), and triglyceride (p < 0.001) levels”
Human trial8-weekn = 61
Nutrients
Multidisciplinary residential program decreases glycated hemoglobin in humans (-0.81%, p < 0.05).
“Glycemic control improved, with reductions in fasting glucose (-16.4 mg/dL), HbA1c (-0.81%), insulin (-2.77 mcU/mL), and HOMA-IR (-0.95; p < 0.05).”
Human trial2-monthn = 61
Nutrients
Helicobacter pylori eradication-treatment regimen + metformin
downin humans1
1 study
Helicobacter pylori eradication-treatment regimen + metformin
downin humans1
Helicobacter pylori eradication-treatment regimen + metformin decreases glycated hemoglobin in humans (Greater reduction of 1.76 percentage points versus eradication-treatment regimen alone (95% CI 1.43–2.09) and 1.77 percentage points versus metformin alone (95% CI 1.41–2.13)).
“Assignment to the Helicobacter pylori eradication-treatment regimen combined with metformin was associated with greater short-term glycated hemoglobin improvement than assignment to either regimen alone.”
Human trialType 2 diabetes mellitus and Helicobacter pylori infection; comparison with either regimen alone using archived summary data6 monthsn = 120
The Journal of international medical research
More on Helicobacter pylori eradication-treatment regimen + metformin
All 64Fewer
Effects
12Kidney failure
mediatesin humans1
1 study
Kidney failure
mediatesin humans1
Glycated hemoglobin is linked with kidney failure in humans (Mediation of the relationship between body mass index and renal failure) (6.83% mediated).
“five acted as mediators in the relationship between BMI and renal failure: cystatin C (12.34%), glucose (7.02%), glycated hemoglobin (HbA1c) (6.83%), diastolic blood pressure (6.37%)”
HumansMediation of the relationship between body mass index and renal failure
Medicine
Lacunar stroke
mediatesin humans1
1 study
Lacunar stroke
mediatesin humans1
Glycated hemoglobin is linked with lacunar stroke in humans (mediating WHRadjBMI effect on lacunar stroke) (23.0% (95% CI, -11.2% to 57.2%)).
“glycated hemoglobin (23.0%; -11.2% to 57.2%)”
Humansmediating WHRadjBMI effect on lacunar stroke
Abdominal Adiposity and Lacunar Stroke: A Mendelian Randomization Mediation Study
medRxivPreprint
Muscle quality index
downin humans1
1 study
Muscle quality index
downin humans1
Glycated hemoglobin is linked with lower muscle quality index in humans (initiating peritoneal dialysis) (β=-0.383, p<0.01).
“HbA1c (β=-0.383; 95% CI: -0.132- to -0.033, R2=0.414)”
Humansinitiating peritoneal dialysisn = 47
Journal of nephrology
Handgrip strength
no changein humans1
1 study
Handgrip strength
no changein humans1
Glycated hemoglobin was not clearly linked with handgrip strength in humans (r=-0.16, p=0.14).
“not in women (r=-0.16, p=0.14).”
Humansfemalesn = 80
Canadian journal of diabetes
Frailty index
upin silico1
1 study
Frailty index
upin silico1
Glycated hemoglobin increases frailty index in silico (β = 0.049, 95% CI: 0.031-0.067, p = 7.39 × 10−8).
“glycated hemoglobin demonstrated significant associations with both the frailty index (β = 0.049, 95% confidence interval: 0.031-0.067, p = 7.39 × 10−8)”
In silico
Assessment of relationships between frailty and diabetes: A two-sample Mendelian randomization study
The Journal of international medical research
Telomere length
mediatesin humans1
1 study
Telomere length
mediatesin humans1
Glycated hemoglobin is linked with telomere length in humans (mediating association of nickel with telomere length) (4.26%).
“associations of nickel and metal mixture with telomere length were partially mediated by glycated hemoglobin, and the mediated proportions were 4.26% and 4.38%, respectively”
Humansmediating association of nickel with telomere length
Biological trace element research
Major bleeding
no changein humans1
1 study
Major bleeding
no changein humans1
Glycated hemoglobin was not clearly linked with major bleeding in humans (non-valvular atrial fibrillation).
“No significant differences were observed in risks of major bleeding or other outcomes in this and other subgroups.”
Humansnon-valvular atrial fibrillation2-yearn = 17,526
Cardiovascular diabetology
Tinnitus
no changein humans1
1 study
Tinnitus
no changein humans1
Glycated hemoglobin was not clearly linked with tinnitus in humans (patients with diabetes).
“No meaningful dependency was found between either patient's gender and tinnitus or the level of fasting blood sugar (FBS) and glycated hemoglobin (HbA1C).”
Humanspatients with diabetesn = 250
Diabetes Mellitus and Tinnitus: an Epidemiology Study
Maedica
Frailty
no changein humans1
1 study
Frailty
no changein humans1
Glycated hemoglobin was not clearly linked with frailty in humans.
“In this study, HbA1c levels showed no significant association to frailty.”
Humansn = 268
Revue medicale de Liege
AUC-C-peptide
downin humans1
1 study
AUC-C-peptide
downin humans1
Glycated hemoglobin is linked with lower AUC-C-peptide in humans (readmitted non-sarcopenia patients).
“Furthermore, as HbA1c and SDBG increased, AUC-C-peptide and AUC-insulin decreased in readmitted non-sarcopenia patients”
Humansreadmitted non-sarcopenia patients
Journal of diabetes and its complications
All 12Fewer
Upstream
6Frailty
upin silico1
1 study
Frailty
upin silico1
Frailty increases glycated hemoglobin in silico.
“frailty was significantly associated with an increased risk of type 2 diabetes mellitus and higher levels of glycated hemoglobin, but not with type 1 diabetes mellitus.”
In silico
Assessment of relationships between frailty and diabetes: A two-sample Mendelian randomization study
The Journal of international medical research
Early weight loss
no changein humans1
1 study
Early weight loss
no changein humans1
Early weight loss showed no clear effect on glycated hemoglobin in humans (≥5% versus <5% early weight loss on tirzepatide).
“Improvements in glycated hemoglobin were similar between subgroups”
Human trial≥5% versus <5% early weight loss on tirzepatide52 weeksn = 893
Diabetes therapy : research, treatment and education of diabetes and related disorders
Glucagon
no changein humans1
1 study
Glucagon
no changein humans1
Glucagon showed no clear effect on glycated hemoglobin in humans (metformin arm; across baseline glucagon subgroups).
“while metformin showed consistent glucose-lowering effects across all glucagon subgroups”
Human trialmetformin arm; across baseline glucagon subgroups1500 mg/day48 weeks
Diabetes research and clinical practice
Trimethylamine N-oxide
no changein humans1
1 study
Trimethylamine N-oxide
no changein humans1
Trimethylamine N-oxide was not clearly linked with glycated hemoglobin in humans.
“Serum TMAO was not associated with longitudinal changes in HbA1c, insulin or HOMA-IR.”
Humansmedian follow-up of 8.9 yearsn = 2,088
Journal of translational medicine
Testosterone
downin humans1
1 study
Testosterone
downin humans1
Testosterone decreases glycated hemoglobin in humans (testosterone therapy in men with baseline T ≥ 264 ng/dl vs < 264 ng/dl) (-3.1 ± 9.2 vs. 3.2 ± 13.9%).
“Men with T ≥ 264 ng/dl showed significant decreases in HbA1c at 12 months (-3.1 ± 9.2 vs. 3.2 ± 13.9%; p = 0.005)”
Human trialtestosterone therapy in men with baseline T ≥ 264 ng/dl vs < 264 ng/dl12 monthsmales
Baseline Testosterone Predicts Body Composition and Metabolic Response to Testosterone Therapy
Frontiers in endocrinology
Idaho stock
downin mice1
1 study
Idaho stock
downin mice1
Idaho stock decreases glycated hemoglobin in mice.
“although GHb levels were significantly lower in the Idaho mice.”
Animals
Experimental gerontology
Associations
55Mild cognitive impairment
upin humans2mixedin humans1OR 1.9
3 studies
Mild cognitive impairment
upin humans2mixedin humans1OR 1.9
Glycated hemoglobin is associated with mild cognitive impairment in humans (HbA1c ≥ 7%) (OR 1.90, 95% CI 1.00-3.60).
“HbA1c ≥ 7% (1.90, 95% CI: 1.00, 3.60).”
HumansHbA1c ≥ 7%
Diabetes, prediabetes, and mild cognitive impairment among older adults: the Hitachi Health Study II
Acta diabetologica
Glycated hemoglobin predicts mild cognitive impairment in humans (patients with type 2 diabetes mellitus; multivariate models).
“The multivariate models consistently identified age, education, disease duration, depression, and glycosylated hemoglobin level as independent predictors.”
Reviewpatients with type 2 diabetes mellitus; multivariate models
Diabetes, metabolic syndrome and obesity : targets and therapy
Glycated hemoglobin predicts mild cognitive impairment in humans (mild cognitive impairment).
“revealed the main predictors of MCI to be changes in glycated hemoglobin, brain-derived neurotrophic factor, and vascular endothelial growth factor-induced neovascularization.”
Reviewmild cognitive impairmentn = 2,023
Journal of bodywork and movement therapies
Frontotemporal dementia
upin humans1mixedin humans1
2 studies
Frontotemporal dementia
upin humans1mixedin humans1
Frontotemporal dementia is associated with glycated hemoglobin in humans (frontotemporal dementia patients compared with controls; GrimAge2 component-level analysis) (p < 0.05).
“Component-level analyses showed increased smoking-related DNA methylation, systemic inflammation (tissue inhibitor of metalloproteinases 1, C-reactive protein), and glucose metabolism (glycated hemoglobin; all p < 0.05).”
Humansfrontotemporal dementia patients compared with controls; GrimAge2 component-level analysisperipheral blood
Frontotemporal dementia linked to faster aging on a DNA clock
Annals of neurology
Glycated hemoglobin is associated with frontotemporal dementia in humans (P non-linearity = 0.006).
“HbA1c showed a U-shaped association with FTD”
Humans
Annals of neurology
Age
mixedin F. albicollis1upin humans1
2 studies
Age
mixedin F. albicollis1upin humans1
Age is associated with glycated hemoglobin in humans (PMOS).
“The 30s group had significantly higher total cholesterol and glycated hemoglobin levels than the <30 group”
HumansPMOS
Journal of clinical medicine
Age is associated with glycated hemoglobin in F. albicollis (free-living population) (Decrease from age 1 to 5 years; increase thereafter).
“Results show a strong decrease in glycated haemoglobin from age 1 to 5 years and an increase thereafter.”
Animalsfree-living populationbloodn = 274
Biology letters
Handgrip strength
downin humans2
2 studies
Handgrip strength
downin humans2
Glycated hemoglobin is associated with handgrip strength in humans (r=-0.47, p=0.002).
“A1C correlated inversely with HGS in men (r=-0.47, p=0.002)”
Humansmalesn = 41
Canadian journal of diabetes
Glycated hemoglobin is associated with handgrip strength in humans (hospitalized older adult inpatients).
“low hemoglobin, and elevated HbA1C levels were independent risk factors for low HGS.”
Humanshospitalized older adult inpatientsn = 135
Frontiers in medicine
Acetate
downin humans1
1 study
Acetate
downin humans1
Acetate is associated with glycated hemoglobin.
“The results revealed that HbA1c was significantly negatively correlated with changes in acetate and total SCFAs.”
Human trial84-day intervention
Frontiers in microbiology
Acetate is associated with glycated hemoglobin in humans Within the high-fiber group; increased fecal acetate versus no increase (25 of 34 participants had increased fecal acetate).
“Within the high-fiber group, participants with increased fecal acetate (25 of 34) had larger glycated hemoglobin reductions at Days 28 and 56”
Human trialWithin the high-fiber group; increased fecal acetate versus no increaseDays 28 and 56n = 34
Frontiers in microbiology
Skeletal muscle mass
downin humans1
1 study
Skeletal muscle mass
downin humans1
Glycated hemoglobin is associated with skeletal muscle mass in humans (r = −0.52).
“The change in ASM / height2 (kg/m2) was also negatively correlated with the change in TAR (r = −0.37, P = 0.027) and HbA1c (r = −0.52, P = 0.001), but positively correlated with the change in TIR (r = 0.36, P = 0.036).”
Human trial4 weeksn = 36
Journal of diabetes investigation
Glycated hemoglobin is associated with skeletal muscle mass in humans.
“The change in ASM / weight (%) was negatively correlated with the change in glycated hemoglobin (%;P = 0.023).”
Human trial4 weeksn = 36
Journal of diabetes investigation
Dementia
downin humans1upin humans1
1 study
Dementia
downin humans1upin humans1
Glycated hemoglobin is linked with a lower risk of dementia in humans (type 2 diabetes, >50% of measurements vs <=50%) (aHR 0.79 (95% CI, 0.77-0.81)).
“HbA1c 6% to <7%: aHR, 0.79 [95% CI, 0.77-0.81]”
Humanstype 2 diabetes, >50% of measurements vs <=50%
Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes
JAMA neurology
Glycated hemoglobin is linked with a higher risk of dementia in humans (type 2 diabetes, >50% of measurements vs <=50%) (aHR 1.74 (95% CI, 1.62-1.86)).
“HbA1c≥10%: aHR, 1.74 [95% CI, 1.62-1.86]”
Humanstype 2 diabetes, >50% of measurements vs <=50%
Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes
JAMA neurology
Empagliflozin or dapagliflozin treatment
downin humans1
1 study
Empagliflozin or dapagliflozin treatment
downin humans1
Empagliflozin or dapagliflozin treatment is associated with glycated hemoglobin in humans (Type 2 diabetes mellitus and diabetic kidney disease; no non-SGLT2 inhibitor control group).
“Over 12 months, glycated hemoglobin and fasting glucose levels decreased”
HumansType 2 diabetes mellitus and diabetic kidney disease; no non-SGLT2 inhibitor control group12 monthsn = 452
Preprints.orgPreprint
Cardio–renal–metabolic integrated education
downin humans1
1 study
Cardio–renal–metabolic integrated education
downin humans1
Cardio–renal–metabolic integrated education is associated with glycated hemoglobin in humans (Adjusted difference −0.52%, 95% CI −0.70 to −0.34).
“Glycaemic control improved (glycated haemoglobin change −0.71% vs −0.19%; adjusted difference −0.52%, 95% confidence interval −0.70 to −0.34; p<0.001).”
HumansChronic heart failure, type 2 diabetes and chronic kidney disease stage 2–4; compared with usual education12 months
Integrated education linked to fewer heart failure admissions
ESC Congress 2026 abstract
Serum tenascin C
downin humans1
1 study
Serum tenascin C
downin humans1
Serum tenascin C is associated with glycated hemoglobin in humans (Patients with prevalent cardiovascular risk factors; bivariate analyses).
“TNC levels correlated negatively with age and glycated hemoglobin and positively with kidney function in bivariate analyses.”
HumansPatients with prevalent cardiovascular risk factors; bivariate analysesn = 274
Tenascin X and Tenascin C Serum Levels in Relation to Age and Cardiometabolic Risk Parameters
International journal of molecular sciences
Glucagon
downin humans1
1 study
Glucagon
downin humans1
Glucagon predicts glycated hemoglobin in humans (acarbose arm; higher baseline glucagon tertile) (-1.32% high and -1.27% medium vs -0.87% low at 24 weeks; -1.23% high and -1.30% medium vs -0.79% low at 48 weeks).
“In the acarbose group, higher baseline glucagon levels correlated with greater HbA1c reductions at 24 weeks”
Human trialacarbose arm; higher baseline glucagon tertile300 mg/day24 and 48 weeks
Diabetes research and clinical practice
Frailty index increase
downin humans1
1 study
Frailty index increase
downin humans1
Glycated hemoglobin is associated with frailty index increase in humans (baseline and average HbA1c levels over time, <7% versus ≥8%) (both P ≤ 0.002).
“Baseline and average HbA1c levels over time of <7%, as compared with ≥8%, were associated with less increase in FI scores over 8 years (both P ≤ 0.002).”
Human trialbaseline and average HbA1c levels over time, <7% versus ≥8%8 yearsn = 4,169
Diabetes care
miR-152
downin humans1
1 study
miR-152
downin humans1
miR-152 is associated with glycated hemoglobin in adults with prediabetes (r=-0.37, P=.024).
“The change in miR-152 positively correlated with the change in levels of the circulating metabolite 25-hydroxyvitamin D (r=0.33, P=.046) and negatively correlated with the change in glycated hemoglobin (r=-0.37, P=.024).”
Human trialin adults with prediabetes
The Journal of nutritional biochemistry
All 55Fewer
Funding
1 grant since 2023Wellcome Trust£4.9M
How this record changed
Summary rewritten as its findings changed.
As it read before
Human trials show exercise lowers glycated hemoglobin after bariatric surgery, in type 2 diabetes with non-alcoholic fatty liver disease, and with whole-body high-intensity interval training in overweight or obesity. A review reports reductions with SGLT2 inhibitors in diabetic chronic kidney disease.
Summary written from the findings.